医薬品連続生産のアジア太平洋市場2020-2087

◆英語タイトル:ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET FORECAST 2020-2028
◆商品コード:INK20MY138
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:117
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥137,500見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGS The Asia Pacific pharmaceutical continuous manufacturing market is anticipated to grow at a CAGR of 9.72% over the forecast period of 2020-2028. A surge in the number of pharmaceutical companies and the rising demand for continuous manufacturing systems is propelling the market growth.

MARKET INSIGHTS
The high growth rate of the Asia Pacific pharmaceutical continuous manufacturing market is further researched by dividing the region into Thailand, Vietnam, India, Japan, South Korea, Indonesia, Australia & New Zealand, China, and the rest of Asia Pacific that includes Malaysia, Philippines, and Singapore. In South Korea, R&D-based pharmaceutical companies are continuously striving for productivity and effectiveness to face the challenges of R&D resources. The industry is driven by highly qualified and experienced R&D manpower, a nationwide collaboration between the industry, academic and public research organizations, strong will for new drug development, and a vision for the global market. In 2020, GEA experts analyzed the advantages of continuous manufacturing to understand the scope of its markets in South Korea. In Thailand, the government is pursuing to make the country a leader for pharmaceuticals and medical devices and a world-class provider of medical care. Thailand is likely to establish a continuous manufacturing process to manufacture pharmaceutical products in a faster and efficient manner.
In countries like Indonesia, the pharmaceutical industry is expected to grow between 12%-13% per annum. Indonesia is home to 30,000 out of the 40,000 medicinal plants known globally. These factors will create demand for pharmaceutical continuous manufacturing. In Vietnam, Sanofi has plans to build a new manufacturing plant, its largest investment to produce pharmaceuticals and healthcare products. The demand from various pharmaceutical industries is driving the market. In the rest of the Asia Pacific region, the growing geriatric population and their dependence on pharmaceutical products are augmenting the market growth.

COMPETITIVE INSIGHTS
Hosokawa Micron Corporation, GEA Group, L.B. Bohle, Pfizer Inc, Eli Lilly, and Company, etc. are some of the prominent companies functioning in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
3.2.2. RISING GOVERNMENTS INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
3.3. KEY RESTRAINTS
3.3.1. INCREASING CUSTOMER ANTICIPATIONS
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. REGULATORY FRAMEWORK
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY PRODUCT
5.1. INTEGRATED CONTINUOUS SYSTEM
5.2. SEMI-CONTINUOUS SYSTEM
5.3. CONTROL & SOFTWARE
6. MARKET BY APPLICATION
6.1. FINAL DRUG PRODUCT MANUFACTURING
6.2. API MANUFACTURING
7. MARKET BY END-USER
7.1. PHARMACEUTICAL COMPANIES
7.2. CONTRACT MANUFACTURING ORGANIZATIONS
7.3. OTHER END-USERS
8. GEOGRAPHICAL ANALYSIS
8.1. ASIA PACIFIC
8.1.1. CHINA
8.1.2. JAPAN
8.1.3. INDIA
8.1.4. AUSTRALIA & NEW ZEALAND
8.1.5. SOUTH KOREA
8.1.6. THAILAND
8.1.7. INDONESIA
8.1.8. VIETNAM
8.1.9. REST OF ASIA PACIFIC
9. COMPANY PROFILES
9.1. COPERION GMBH
9.2. ELI LILLY & COMPANY
9.3. GEA GROUP AG
9.4. GEBRUDER LODIGE MASCHINENBAU GMBH
9.5. GLATT GMBH
9.6. HOSOKAWA MICRON CORPORATION
9.7. KORSCH AG
9.8. L.B. BOHLE MASCHINEN + VERFAHREN GMBH
9.9. MUNSON MACHINERY COMPANY
9.10. PFIZER INC
9.11. SIEMENS HEALTHINEERS
9.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
9.13. THERMO FISHER SCIENTIFIC INC



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[医薬品連続生産のアジア太平洋市場2020-2087]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆